What Alexandria Real Estate Equities, Inc. told the SEC could break it.

Over a third of in-licensed molecules at major U.S. pharma companies now originate from Chinese firms; if biopharma keeps sourcing innovation from China rather than developing it domestically, U.S. biotech investment and demand for Alexandria's laboratory space could decline.

“If biopharmaceutical companies increasingly rely on acquiring or in-licensing assets from China instead of those developed in the U.S., it could negatively impact the fundamentals of the U.S. biotechnology market, leading to reduced investment and fewer U.S.-based biotechnology companies. Should this occur, demand for domestic laboratory space could decline.”

As a lab/life-science landlord, Alexandria's demand depends on biopharma tenant health; new U.S. pharmaceutical tariffs (estimated +$46B in industry costs, partially capped at 15% under the Aug 2025 US-EU accord) raise tenant costs and threaten lab-space demand.

“In 2024, over $200 billion in pharmaceutical products were imported to the U.S., and it is estimated that U.S. tariffs could add $46 billion in costs to the pharmaceutical industry. On August 21, 2025, the U.S. and the European Union reached a trade agreement establishing a 15% ceiling on tariffs applied to pharmaceutical products traded between the two regions.”